Search results for "Calcitonin"

showing 10 items of 106 documents

Immunological features of coronavirus disease 2019 in patients with cancer.

2020

Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has caused a major pandemic. Patients with cancer are at higher risk of severe COVID-19. We aimed to describe and compare the immunological features of cancer patients hospitalised for COVID-19 or other concomitant, cancer-related illness. Methods In this prospective study, the clinical and immunological characteristics of 11 cancer patients with COVID-19 and 11 non–COVID-19 cancer patients hospitalised in the same unit at the same period for other medical issues were analysed. We also used 10 healthy volunteers as controls. Peripheral immune parameters were analysed using multiparamet…

0301 basic medicineCD4-Positive T-LymphocytesMaleCancer ResearchTime Factors[SDV]Life Sciences [q-bio]Pneumonia ViralHuman leukocyte antigenCD8-Positive T-LymphocytesProcalcitonin03 medical and health sciencesBetacoronavirus0302 clinical medicineImmune systemNeoplasmsMedicineCytotoxic T cellHumansProspective StudiesPandemicsOriginal ResearchCancerAgedbusiness.industrySARS-CoV-2MonocyteCancerCOVID-19medicine.disease3. Good healthImmunomonitoring[SDV] Life Sciences [q-bio]030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunologyTumor necrosis factor alphaFemaleFrancebusinessCoronavirus InfectionsCD8T-Lymphocytes CytotoxicEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Triptans and CGRP blockade - impact on the cranial vasculature.

2017

Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and mig…

0301 basic medicineMigraine DisordersCalcitonin gene related peptide – CGRPNeuropeptidelcsh:MedicineMigraine modelsReviewTriptansReview ArticleCalcitonin gene-related peptide03 medical and health sciences0302 clinical medicineJournal ArticlemedicineHumansMigraine treatmentReceptorbusiness.industryTriptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models Magnetic resonance angiography (MRA)Anti-CGRP (receptor) monoclonal antibodies – mAbsTrigeminovascular systemlcsh:RTriptansGeneral MedicineMiddle meningeal arterymedicine.diseaseTryptamines3. Good healthMagnetic resonance angiography (MRA)Middle cerebral arteries030104 developmental biologyAnesthesiology and Pain MedicineMigraineAnesthesiaNeurology (clinical)SerotoninbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugReceptors Calcitonin Gene-Related PeptideThe journal of headache and pain
researchProduct

Non-Rapid Eye Movement Sleep Parasomnias and Migraine: A Role of Orexinergic Projections

2018

Introduction: Sleep and migraine share a common pathophysiological substrate, although the underlying mechanisms are unknown. The serotonergic and orexinergic systems are both involved in the regulation of sleep/wake cycle, and numerous studies show that both are involved in the migraine etiopathogenesis. These two systems are anatomically and functionally interconnected. Our hypothesis is that in migraine a dysfunction of orexinergic projections on the median raphe (MR) nuclei, interfering with serotonergic regulation, may cause Non-Rapid Eye Movement parasomnias, such as somnambulism. Hypothesis/theory: Acting on the serotonergic neurons of the raphe nuclei, the dysfunction of orexinergic…

0301 basic medicineSerotonergic systemMigraine; Orexinergic system; Pro-inflammatory peptides; Serotonergic system; Sleep-wake rhythm; Neurology; Neurology (clinical)Substance PCalcitonin gene-related peptidePro-inflammatory peptideSerotonergicNon-rapid eye movement sleeplcsh:RC346-429sleep–wake rhythmMigraine; Orexinergic system; Pro-inflammatory peptides; Serotonergic system; Sleep-wake rhythm;Settore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'Educazione03 medical and health sciencesTrigeminal ganglionchemistry.chemical_compound0302 clinical medicinePro-inflammatory peptidesSleep-wake rhythmHypothesis and TheoryMedicinelcsh:Neurology. Diseases of the nervous systemMigraineMigraine; Orexinergic system; Pro-inflammatory peptides; Serotonergic system; Sleep-wake rhythmbusiness.industryOrexinergic systemserotonergic system orexinergic system sleep–wake rhythm migraine pro-inflammatory peptidesSettore MED/39 - Neuropsichiatria InfantileOrexin030104 developmental biologyNeurologychemistryNeurology (clinical)SerotoninbusinessRaphe nucleiNeuroscience030217 neurology & neurosurgeryNeuroscienceFrontiers in Neurology
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin.

2016

Calcitonin gene related peptide (CGRP) and substance P (SP) are neuropeptides that are simultaneously released from nociceptive C-fibers. CGRP is a potent vasodilator, inducing a long-lasting increase in superficial skin blood flow, whereas SP induces only a brief vasodilation but a significant plasma extravasation. CGRP and SP may play important roles in the pathophysiology of various pain states but little is known about their interaction. Different concentrations of SP (ranging from 10-5M to 10-9M) were applied to the volar forearm of 24 healthy subjects via dermal microdialysis. SP was applied either alone or in combination with CGRP10-9M and CGRP 10-6M. As expected, SP induced a transi…

0301 basic medicinemedicine.medical_specialtyMicrodialysisCalcitonin Gene-Related PeptideVasodilationSubstance PCalcitonin gene-related peptideSubstance P03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundYoung Adult0302 clinical medicineEndocrinologyInternal medicinemedicineHumansNeprilysinSkinReceptor activity-modifying proteinintegumentary systemDose-Response Relationship DrugEndocrine and Autonomic SystemsChemistryGeneral MedicineCALCRLExtravasationVasodilationForearm030104 developmental biologyEndocrinologyNeurologyRegional Blood Flow030217 neurology & neurosurgeryNeuropeptides
researchProduct

Blocking CGRP in migraine patients – a review of pros and cons

2017

Abstract Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: …

0301 basic medicinemedicine.medical_specialtyanesthesiology and pain medicineNeurologyCalcitonin Gene-Related PeptideMigraine DisordersCentral nervous systemlcsh:MedicineNeurological disorderReview ArticleCalcitonin gene-related peptidePlaceboBioinformatics03 medical and health sciencesEpilepsy0302 clinical medicineCalcitonin Gene-Related Peptide Receptor AntagonistsMedicineAnimalsHumansMigraineneurology (clinical)integumentary systembusiness.industrylcsh:Racute treatment; CGRP; CGRP receptor; gepants; migraine; prophylactic treatment; neurology (clinical); anesthesiology and pain medicineCgrp receptorGeneral MedicineGepantsmedicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureMigrainenervous systemAnesthesiaAcute treatment; Cgrp; Cgrp receptor; Gepants; Migraine; Prophylactic treatment; Neurology (clinical); Anesthesiology and Pain MedicineCgrpAnimal studiesbusinessGepantProphylactic treatmentAcute treatment030217 neurology & neurosurgery
researchProduct

Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher d…

2018

Anca Zimmermann,1 Radu A Popp,2 Heidi Rossmann,3 Simona Bucerzan,4 Ioana Nascu,4 Daniel Leucuta,5 Matthias M Weber,1 Paula Grigorescu-Sido41Department of Endocrinology and Metabolic Diseases, 1st Clinic and Polyclinic of Internal Medicine, University of Mainz, Mainz, Germany; 2Department of Medical Genetics, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 3Institute for Clinical Chemistry and Laboratory Medicine, University of Mainz, Mainz, Germany; 4Center of Genetic Diseases, 1st Pediatric Clinic, University of Medicine and Pharmacy, Cluj-Napoca, Romania; 5Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy, Cluj-Napoca, RomaniaPurpose: Oste…

0301 basic medicinemusculoskeletal diseasesmedicine.medical_specialtyTherapeutics and Clinical Risk ManagementOsteoporosisGaucher diseasegene variantsCalcitriol receptorBone remodeling03 medical and health sciencesOsteoprotegerinInternal medicineGenotypecalcitonin receptormedicinevitamin D receptorPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsCalcitonin receptorOriginal ResearchChemical Health and Safetybiologybusiness.industryGeneral Medicinemedicine.diseaseosteoporosis030104 developmental biologyEndocrinologyosteoprotegerinOsteocalcinbiology.proteinbusinessSafety ResearchEstrogen receptor alphaTherapeutics and Clinical Risk Management
researchProduct

Clinical utility of biochemical markers for the prediction of COVID-19-related mortality in kidney transplant recipients

2021

International audience

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)[SDV]Life Sciences [q-bio]030232 urology & nephrologykidney transplantationInflammation030204 cardiovascular system & hematologyKidney transplantProcalcitonin03 medical and health sciences0302 clinical medicineMedicineKidney transplantationBiochemical markersComputingMilieux_MISCELLANEOUSbiologybusiness.industrytroponinbiomarkersCOVID-19medicine.diseaseTroponinResearch Letters3. Good health[SDV] Life Sciences [q-bio]NephrologyinflammationD-dimerImmunologybiology.proteinmedicine.symptombusinessprocalcitonin
researchProduct

Association of Serum Procalcitonin With Cardiovascular Prognosis in Coronary Artery Disease

2011

Background: Procalcitonin (PCT) is an established biomarker for the diagnosis of sepsis. Evidence is growing that PCT concentration correlates with the extent of atherosclerosis and prognosis in patients with coronary artery disease (CAD). Methods and Results: A total of 2,131 patients with CAD were followed up for a median of 3.6 years. During follow-up, death from cardiovascular causes was registered in 95 patients and non-fatal myocardial infarction in 85 patients. Median and quartile 1 and 3 are reported for PCT concentration. Patients who died of cardiovascular causes had higher PCT concentrations [0.021 (0.012/0.036) ng/ml vs. 0.015 (0.010/0.023) ng/ml; P<0.0001]. Patients with acute …

Acute coronary syndromemedicine.medical_specialtyProportional hazards modelbusiness.industryHazard ratioGeneral Medicinemedicine.diseaseConfidence intervalProcalcitoninSurgeryCoronary artery diseaseInternal medicineparasitic diseasesmedicineCardiologyMyocardial infarctionCardiology and Cardiovascular MedicinebusinessSurvival ratehormones hormone substitutes and hormone antagonistsCirculation Journal
researchProduct

Prophylactic Thyroidectomy in 75 Children and Adolescents with Hereditary Medullary Thyroid Carcinoma: German and Austrian Experience

1998

When mutations of the RETproto-oncogene were found in 1993 to account for hereditary medullary thyroid carcinoma (MTC), surgeons obtained the opportunity to operate on patients prophylactically (i. e., at a clinically asymptomatic stage). Whether this approach is justified, and, if so, when and to which extent surgery should be performed remained to be clarified. A questionnaire was sent to all surgical departments in Germany and Austria. All of the patients who fulfilled the following criteria were enrolled: (1) preoperatively proved RET mutation; (2) age/= 20 years, (3) clinically asymptomatic thyroid C cell disease; and (4) TNM classification pT0-1/pNX/pN0-1/M0. Seventy-five patients wer…

AdultCalcitoninMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAsymptomaticThyroid carcinomaNeoplastic Syndromes HereditaryGermanymedicineCarcinomaHumansChildLymph nodebusiness.industryThyroidThyroidectomymedicine.diseaseSurgerymedicine.anatomical_structureHypoparathyroidismCalcitoninAustriaCarcinoma MedullaryChild PreschoolThyroidectomyFemaleSurgerymedicine.symptombusinessWorld Journal of Surgery
researchProduct